文献速递鼻科

温度控制射频神经消融治疗慢性鼻炎:随机对照试验治疗后12个月结局

Temperature-controlled radiofrequency neurolysis for treatment of chronic rhinitis: 12-month outcomes after treatment in a randomized controlled trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2022-07-05

这项前瞻性、多中心、患者盲法随机对照试验报告了温度控制射频(TCRF)神经消融治疗慢性鼻炎12个月结局。主要活动治疗组(n=77)12个月应答率为80.6%(n=67),rTNSS平均变化为-4.8(95%CI -5.5至-4.1;p<0.001),即改善57.8%。截至当时试验未报告严重不良事件,报告8例与器械/操作相关的不良事件。

要点

  • 主要活动治疗组12个月应答率为80.6%(n=67),95%CI 69.1%-89.2%。
  • 主要活动治疗组12个月rTNSS平均变化为-4.8(95%CI -5.5至-4.1;p<0.001),改善57.8%。
  • 截至当时试验未报告严重不良事件,报告8例与器械/操作相关的不良事件。

核心结论

  • TCRF神经消融治疗鼻后神经(PNN)区域是安全的,3个月时优于假手术的症状负担改善持续至12个月。

研究设计与样本

  • 前瞻性、多中心、患者盲法随机对照试验;主要活动治疗组77例,假手术对照组交叉后活动治疗组27例。

主要发现

  • 主要活动治疗组(n=77)基线rTNSS均值为8.3(95%CI 7.9-8.7)。
  • 12个月时应答率为80.6%(n=67)(95%CI 69.1%-89.2%)。
  • 12个月时rTNSS平均变化为-4.8(95%CI -5.5至-4.1;p<0.001),即改善57.8%。
  • 交叉活动治疗组(n=27)可获得的初始rTNSS-based结局与主要治疗组趋势相同。
  • 截至当时试验未报告严重不良事件,报告8例与器械/操作相关的不良事件。

关键数值与推荐

  • 应答者定义为24小时回顾性总鼻症状评分(rTNSS)较基线改善(降低)≥30%。
  • 入组标准包括rTNSS≥6,伴中重度流涕和轻重度鼻塞。
  • TCRF笔式电极双侧应用于PNN区域非重叠区域。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Temperature-controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve (PNN) area for the treatment of chronic rhinitis was previously reported as superior to a sham-control procedure at 3 months postprocedure in a randomized controlled trial (RCT). The primary endpoint was a responder rate of ≥30% improvement (decrease) for 24-hour reflective total nasal symptom score (rTNSS) compared with baseline. Herein, 12-month outcomes after active treatment are reported. METHODS: In this prospective, multicenter, patient-blinded RCT, patients in the index active treatment arm were unblinded at 3 months and followed through 12 months. At 3 months, eligible patients from the sham-control arm of the study were invited to crossover to active treatment. Eligibility criteria included rTNSS ≥6, with moderate-severe rhinorrhea and mild-severe congestion. The TCRF stylus was applied bilaterally to nonoverlapping areas in the region of the PNN. RESULTS: Patients in the index active treatment arm (n = 77) had a mean baseline rTNSS of 8.3 (95% confidence interval [CI], 7.9-8.7). At 12 months, the responder rate was 80.6% (n = 67) (95% CI, 69.1%-89.2%). At 12 months, the mean change in rTNSS was -4.8 (95% CI, -5.5 to -4.1; p < 0.001), a 57.8% improvement. The available initial rTNSS-based outcomes in the crossover active treatment arm (n = 27) were following the same course as the index treatment arm. No serious adverse events and 8 adverse events related to the device/procedure were reported in the trial to date. CONCLUSION: TCRF neurolysis of the PNN area is safe and the symptom burden improvement that was superior to a sham procedure at 3 months was sustained through 12 months.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Takashima M, Stolovitzky JP, Ow RA, et al. Temperature-controlled radiofrequency neurolysis for treatment of chronic rhinitis: 12-month outcomes after treatment in a randomized controlled trial. Int Forum Allergy Rhinol. 2022. PMID: 35714267. doi:10.1002/alr.23047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。